The VES-13, a brief frailty screening tool, was found effective in determining which older patients with GU cancer were at higher risk for adverse outcomes and would benefit from a CGA.
Patients with GU malignancies were more likely to receive palliative care if they were in the West compared with other US regions.
Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.
Health care providers ordering meds should view ‘too good to be true’ offers with suspicion, agency says.
